Evaluation of AZD8154 Concentrations in Blood

A Randomised, 3 Period, Single Dose, Open-label Crossover Study to Evaluate the Systemic Exposure of AZD8154 While Administered Via Inhalation Using a Nebuliser Formulation and a Monodose Dry Powder Inhaler (DPI) Formulation in Healthy Subjects

This study is intended to evaluate the systemic pharmacokinetic (PK) characteristics and the safety of AZD8154 following administration of the Monodose DPI formulation compared with the administration of the nebuliser suspension.

Study Overview

• Status: Terminated
• Conditions: Asthma
• Intervention / Treatment: Drug: AZD8154 nebuliser; Drug: AZD8154 Monodose DPI presented in capsules; Drug: AZD8154 Placebo Monodose DPI presented in capsules

Detailed Description

This study will be a randomised, open-label, 3-period, single-dose, single-centre, crossover study in healthy males and healthy females of non-childbearing potential.

The study will comprise:

• A Screening Period of maximum 28 days;
• Three treatment periods during which subjects will be resident at the Clinical Unit from the morning of the day before dosing with AZD8154 or placebo (Day 1) until 72 hours following dosing for collection of PK samples; discharged on the morning of Day 4 of each treatment period;
• A Follow up Visit within 6 ± 1 days after last dose administration of investigational medicinal products (IMPs) (i.e., AZD8154 or placebo).

A total of 15 healthy subjects will be randomised in this study to ensure that at least 12 subjects are evaluable.

Each subject will be involved in the study for approximately 9 weeks.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 1

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 14050
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Provision of signed and dated, written informed consent prior to any study specific procedures.
2. Healthy male and/or healthy female subjects of non childbearing potential aged 18 to 55 years (inclusive at the Screening Visit) with suitable veins for cannulation or repeated venipuncture.

3. Females must have a negative pregnancy test at Screening Visit and on admission to the Clinical Unit, must not be lactating and must be of non childbearing potential, confirmed at Screening by fulfilling 1 of the following criteria (i) Females are considered postmenopausal if they have had amenorrhea for at least 12 months without an alternative medical cause. The following age specific requirements apply: Women under 50 years old are considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments and with luteinising hormone and follicle stimulating hormone levels are in the postmenopausal range.

   Women over 50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments.

   (ii) Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

4. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 60 kg and no more than 100 kg inclusive.
5. Subject has a forced expiratory volume in 1 second ≥ 80% of the predicted value regarding age, height, gender and ethnicity at the Screening Visit.

Exclusion Criteria:

1. History of any clinically significant disease or disorder which, in the opinion of the Principal Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
2. Subject is immune compromised.
3. History of diabetes, impaired fasting glucose, metabolic syndrome, hypertriglyceridemia or familial lipid disorders.
4. Current or previous history of malignancy of any kind except cutaneous basal or squamous cell carcinoma successful treated with therapy.
5. History of any respiratory disorders such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis (IPF), or infantile bronchiolitis.
6. Subject with latent or active tuberculosis, as confirmed by a positive QuantiFERON® TB Gold test or as judged by the Investigator at the Screening Visit.
7. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs, or bowel disorders not otherwise specified.
8. Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the IMP.

9. Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results, defined as the following:

   (i) Alanine aminotransferase and/or aspartate aminotransferase > 1.5 x the upper limit of the normal (ULN) laboratory range.

   (ii) Bilirubin > 1.5 times the ULN laboratory range. (iii) Absolute neutrophil count < lower limit of normal (LLN). (iv) Absolute lymphocyte count < LLN.

10. Any positive result at the Screening Visit for serum hepatitis B surface antigen OR hepatitis B core antibodies, hepatitis C virus antibody (anti HCV) and human immunodeficiency virus.

11. Abnormal vital signs, after 5 minutes supine rest, defined as any of the following:

    (i) Systolic blood pressure (BP) < 90 mmHg or > 140 mmHg. (ii) Diastolic BP < 50 mmHg or > 90 mmHg. (iii) Pulse < 50 or > 90 beats per minute (bpm).

12. Any clinically important abnormalities in rhythm, conduction or morphology of the 12 lead safety ECG as judged by the Investigator.

    (i) Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF) > 450 ms or shortened QTcF < 340 ms or family history of long QT syndrome.

    (ii) PR (PQ) interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre excitation).

    (iii) PR (PQ) interval prolongation (> 220 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third degree atrioventricular (AV) block, or AV dissociation.

    (iv) Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms. Subjects with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of e.g., ventricular hypertrophy or pre excitation.

13. Previous use of a mechanistic target of rapamycin (mTOR) antagonist (e.g., rapamycin, everolimus) or PI3K inhibitor (selective or non selective PI3K inhibitors).
14. Known or suspected history of drug abuse as judged by the Investigator.
15. Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the previous 3 months.
16. History of alcohol abuse or excessive intake of alcohol as judged by the Investigator.
17. Positive screen for drugs of abuse or cotinine (nicotine) at the Screening Visit or admission to the Clinical Unit or positive screen for alcohol on admission to the Clinical Unit before the first administration of the IMP.
18. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD8154.
19. Receipt of live attenuated vaccines 2 months before first administration of the IMP and 3 months after the last IMP administration.
20. Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate) as judged by the Investigator.
21. Use of drugs with cytochrome P450 (CYP) 3A enzyme inducing or inhibition properties within 3 weeks before first administration of IMP.
22. Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks before the first administration of the IMP or longer if the medication has a long half life.
23. Plasma donation within 1 month of the Screening Visit or any blood donation/blood loss > 500 mL during the 2 months before the Screening Visit.
24. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration the IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest.
25. Involvement of any Astra Zeneca or study site employee or their close relatives.
26. Judgement by the Investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the Screening Period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
27. Subjects who cannot communicate reliably with the Investigator and/or is not able to read speak and understand the German language.
28. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship or committed to an institution by governmental or juridical order.
29. Subject has a positive test result for SARS-CoV-2 RT-PCR before randomisation.
30. Subject has clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnoea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on first admission.
31. History of severe COVID-19 (hospitalisation, extracorporeal membrane oxygenation, mechanically ventilated).
32. Subjects who are regularly exposed to COVID-19 as part of their daily life (e.g., health care professionals working in COVID-19 wards or at emergency departments).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AZD8154 nebuliser suspension; The study subjects will receive 1 mg delivered dose of AZD8154 nebuliser suspension	Drug: AZD8154 nebuliser; Nebuliser suspension
Experimental: AZD8154 Monodose; The study subjects will receive 1 mg capsule delivered dose of AZD8154 Monodose DPI formulation	Drug: AZD8154 Monodose DPI presented in capsules; AZD8154 Monodose DPI formulation delivered dose
Placebo Comparator: AZD8154 Placebo Monodose DPI; The study subjects will receive AZD8154 placebo Monodose DPI formulation dosed to correspond to 1 mg delivered dose AZD8154 Monodose DPI formulation	Drug: AZD8154 Placebo Monodose DPI presented in capsules; The dose correspond to AZD8154 Monodose DPI formulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the plasma concentration time curve from zero to infinity (AUCinf)	To evaluate the PK characteristics of AZD8154 following inhaled single dose administration of a Monodose DPI formulation when compared with inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48 and 72 hours post dose)
Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast)	To evaluate the PK characteristics of AZD8154 following inhaled single dose administration of a Monodose DPI formulation when compared with inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48 and 72 hours post dose)
Maximum observed plasma (peak) drug concentration (Cmax)	To evaluate the PK characteristics of AZD8154 following inhaled single dose administration of a Monodose DPI formulation when compared with inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48 and 72 hours post dose)
Dose normalised AUCinf	To evaluate the PK characteristics of AZD8154 following inhaled single dose administration of a Monodose DPI formulation when compared with inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48 and 72 hours post dose)
Dose normalised AUClast	To evaluate the PK characteristics of AZD8154 following inhaled single dose administration of a Monodose DPI formulation when compared with inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48 and 72 hours post dose)
Dose normalised Cmax	To evaluate the PK characteristics of AZD8154 following inhaled single dose administration of a Monodose DPI formulation when compared with inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48 and 72 hours post dose)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to reach peak or maximum observed concentration or response following drug administration (tmax)	To evaluate further PK parameters of AZD8154 following inhaled single dose administration of a Monodose DPI formulation and an inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 12, 18, 24, 36, 48 and 72 hours post dose)
Half life associated with terminal slope of a semi logarithmic concentration time curve (t½λz)	To evaluate further PK parameters of AZD8154 following inhaled single dose administration of a Monodose DPI formulation and an inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 12, 18, 24, 36, 48 and 72 hours post dose)
Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRT)	To evaluate further PK parameters of AZD8154 following inhaled single dose administration of a Monodose DPI formulation and an inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 12, 18, 24, 36, 48 and 72 hours post dose)
Terminal elimination rate constant (λz)	To evaluate further PK parameters of AZD8154 following inhaled single dose administration of a Monodose DPI formulation and an inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 12, 18, 24, 36, 48 and 72 hours post dose)
Apparent total body clearance of drug from plasma after extravascular administration (CL/F)	To evaluate further PK parameters of AZD8154 following inhaled single dose administration of a Monodose DPI formulation and an inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 12, 18, 24, 36, 48 and 72 hours post dose)
Volume of distribution following extravascular administration (based on terminal phase) (Vz/F)	To evaluate further PK parameters of AZD8154 following inhaled single dose administration of a Monodose DPI formulation and an inhaled single dose administration of a nebuliser suspension.	Study Day 1 to 4 (Pre dose, 10 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 12, 18, 24, 36, 48 and 72 hours post dose)
Number of subjects with adverse events	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	Day-1, 1 to 4 (Spontaneous plus pre dose, 3, 12, 24, 48 and 72 hrs post dose)
Number of subjects with abnormal blood pressure	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 (Predose and 72hrs post dose)
Number of subjects with abnormal pulse rate	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 (Predose and 72hrs post dose)
Number of subjects with abnormal tympanic temperature	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day 1 to 4 (Predose, 24, 48, and 72 hrs post dose)
Number of subjects with abnormal respiratory rate	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 (Predose and 72hrs post dose)
Number of subjects with abnormal ECG	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day 1 to 4 (Predose and 72 hrs post dose)
Number of subjects with abnormal physical examination	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit
Number of subjects with abnormal spirometry	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening(Day-28 to-2), Day-1, Day1 to 4 (Predose and 30min, 90min, 3hrs, 12hrs and 24hrs postdose)
Number of subjects with abnormal White blood cell (WBC) count	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Red blood cell (RBC) count	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Haemoglobin (Hb)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Haematocrit (HCT)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Mean corpuscular volume (MCV)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Mean corpuscular haemoglobin (MCH)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Mean corpuscular haemoglobin concentration (MCHC)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Neutrophils absolute count	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Lymphocytes absolute count	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Monocytes absolute count	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Eosinophils absolute count	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Basophils absolute count	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Platelets	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Reticulocytes absolute count	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Sodium	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Potassium	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Urea	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Creatinine	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Albumin	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Calcium	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Phosphate	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Glucose(fasting)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal C-reactive protein (CRP)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Alkaline phosphatase (ALP)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Alanine aminotransferase (ALT)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Aspartate aminotransferase (AST)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Gamma glutamyl transpeptidase (GGT)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Total Bilirubin (TBL)	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Unconjugated bilirubin	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)
Number of subjects with abnormal Urinalysis	To assess the safety of single doses of AZD8154 (Monodose DPI formulation and nebuliser suspension) or placebo (Monodose DPI formulation) in healthy subjects. The parameters to be assessed are glucose, protein and blood in urine	At screening (Day-28 to-2), Day-1, Day1 to 4 and follow-up visit (6± 1 days post last dose)

Collaborators and Investigators

• Sponsor: AstraZeneca
• Collaborators: Parexel

Study record dates

Study Major Dates

• Study Start (Actual): July 17, 2020
• Primary Completion (Actual): September 2, 2020
• Study Completion (Actual): September 2, 2020

Study Registration Dates

• First Submitted: July 17, 2020
• First Submitted That Met QC Criteria: July 17, 2020
• First Posted (Actual): July 21, 2020

Study Record Updates

• Last Update Posted (Actual): August 24, 2021
• Last Update Submitted That Met QC Criteria: August 23, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Keywords: Phase 1, Phosphoinositide 3-kinase inhibitor, open-label crossover study
• Other Study ID Numbers: D8900C00005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No